Marginal Bone Loss, Peri-implant Bone Loss, Peri-Implant Health, Peri-implant Marginal Bone Loss
Conditions
Keywords
implant, marginal bone loss, peri-implant sulcular fluid, sclerostin, calprotectin, matrix metalloproteinases, n-terminal type I collagen telopeptide
Brief summary
This study aimed to compare biological mediators known to be important in peri-implant diseases in implants with and without early stage marginal bone loss. A total of 118 implants in 59 patients were designated as test and control groups. The radiographic and periodontal data of the included implants, along with peri-implant sulcus fluid samples, were evaluated.
Detailed description
This study included clinical and radiographic records of patients who received implant treatment in the maxilla and/or mandible between 11/2021 and 9/2024. Patients were divided into test and control groups based on the presence/absence of EMBL after prosthetic loading. Periodontal clinical measurements were recorded and peri-implant sulcus fluid (PISF) samples were collected. Sclerostin, calprotectin, type I collagen cross-linked N-telopeptide (NTx), matrix metalloproteinase (MMP)-8, and MMP-9 levels were analyzed using ELISA. Group comparisons were performed with the statistical analyses.
Interventions
OTHERCollecting of peri-implant sulcus fluid
To evaluate biomarkers associated with peri-implant bone loss, periopaper was placed in the peri-implant pocket and absorbed with sulcus fluid.
DIAGNOSTIC_TESTPeriapical radiography
Parallel cone technique was used during periapical imaging to accurately measure peri-implant bone loss.
Sponsors
Pamukkale University
Pamukkale University scientific research project department
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Presence of 1 mm or more of radiographic marginal bone loss within the first 3 months after implant placement * Availability of radiographic documentation * Availability of demographic data, surgical records, and data related to the implant used * Physical condition classified as Class I and II according to the American Society of Anesthesiologists (ASA) classification * Patients with no smoking history in the last 10 years * Fixed implant-supported restorations * Screw-retained implants
Exclusion criteria
* Patients receiving and/or maintaining implant treatment at centers other than the Department of Periodontology, Pamukkale University Faculty of Dentistry * Patients with incomplete or unreachable files or radiographic documentation * Patients with a known systemic disease/condition that alters their physical condition or bone metabolism * Severe bruxism cases * Pregnant and breastfeeding patients * Patients with incomplete implant-supported prosthesis * Areas grafted during or before implant surgery * Removable implant-supported restorations * Cement-retained implants * Patients undergoing peri-implantitis treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Calprotectin levels in peri-implant crevicular fluid | 6-8 week after prosthetic treatment | After collecting peri-implant sulcus fluid using the paper strip method, calprotectin levels in the peri-implant sulcus region were determined using the ELISA method and recorded in ng/ml. |
| Sclerostin levels in peri-implant crevicular fluid | 6-8 week after prosthetic treatment | After collecting peri-implant sulcus fluid using the paper strip method, sclerostin levels in the peri-implant sulcus region were determined using the ELISA method and recorded in pg/ml. |
| NTx levels in peri-implant crevicular fluid | 6-8 week after prosthetic treatment | After collecting peri-implant sulcus fluid using the paper strip method, NTx levels in the peri-implant sulcus region were determined using the ELISA method and recorded in ng/ml. |
| MMP-8 levels in peri-implant crevicular fluid | 6-8 week after prosthetic treatment | After collecting peri-implant sulcus fluid using the paper strip method, MMP-8 levels in the peri-implant sulcus region were determined using the ELISA method and recorded in ng/ml. |
| MMP-9 levels in peri-implant crevicular fluid | 6-8 week after prosthetic treatment | After collecting peri-implant sulcus fluid using the paper strip method, MMP-9 levels in the peri-implant sulcus region were determined using the ELISA method and recorded in ng/ml. |
Countries
Turkey (Türkiye)
Contacts
PRINCIPAL_INVESTIGATORRaziye Tugce Can Keles, R.A.
Pamukkale University Faculty of Dentistry, Department of Periodontology
STUDY_DIRECTORGizem Torumtay Cin, Assoc. Prof.
Pamukkale University Faculty of Dentistry, Department of Periodontology
Outcome results
None listed